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Chapter 12 
UNITED STATES: SEXUAL BEHAVIOR IN 
ASSOCIATION WITH HUMAN PAPILLOMA 
VIRUS VACCINATION IN YOUNG GIRLS 
Wafa RR Al Romaih, MD, Said Shahtahmasebi, PhD 
and Hatim A Omar, MD'" 
Division of Adolescent Medicine, Department of Pediatrics, 
University of Kentucky, Lexington, Kentucky, United States of America 
The first human Papilloma virus (HPV) vaccine was approved in the 
United States in 2006 with the potential to reduce cervical cancer and 
genital warts. Since then, its efficacy in preventing HPV -related cancers 
in both males and females has been promising. Despite CDC 
recommendations, opponents of the vaccine assert that vaccinating pre-
adolescents and adolescents will increase their sexual activity, as well as 
overtly condone risky sexual behavior. We analyzed clinic data of 499 
adolescents with a mean age of 16 years to explore whether vaccination 
led to change in sexual behavior after one year. Our results showed no 
statistically significant difference in either initiation of sexual activity or 
change in sexual behavior when compared to peers, therefore refuting the 
assertion that this method of preventative healthcare promotes 
promiscuity. Thus, we conclude that teenage sexual behavior is linked 
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more closely to ethics, morality, and other socio-cultural phenomena 
rather than HPV vaccine itself. 
INTRODUCTION 
The human papillomavirus (HPV) is the most common sexually transmitted 
infection in the United States (1). The virus specifically targets the stratified 
epithelium of skin and mucous membranes. The infection can result in a 
spectrum of conditions including skin and anogenital warts, various anogenital 
malignancies, and in some cases with nongenital manifestations. While there 
are more than one hundred subtypes of the virus, the most common include the 
low risk subtypes, 6 and 11, and the higher risk subtypes, 16 and 18. It is 
estimated that these four subtypes alone result in more than 90% of the cases 
of genital warts, and about 70% of the cases of cervical cancer (2-4). 
In 2006, the first vaccine against HPY was approved by the Food and 
Drug Administration (FDA) for use in females aged 9 to 26 years old in a 
tetravalent form targeting subtypes 6, 11, 16 and 18 (5). A bivalent version 
targeting types 16 and 18 was later approved in 2009 for prevention of cervical 
cancer and other precancerous lesions, also in females (6). As these vaccines 
were made available, the CDC's advisory committee on immunization 
practices (ACIP) concomitantly recommended routine vaccination of females 
11-12 years old, or catch up vaccination in females aged 13-26 irrespective of 
previous sexual activity, as well as in male aged 9-26 (7,8), ultimately 
sparking a great debate across the world. Given that the last time the vaccine-
cancer link was realized in the 1980s with the hepatitis B vaccine and 
hepatocellular cancer, the HPY vaccine was viewed with great promise. 
The efficacy of the vaccine itself in prevention of an array of cancers, 
including cervical, penile, vulvar, vaginal, and anal cancer, and precancerous 
lesions (9-11) would at first glance seem to outweigh any possible 
disadvantages. Early studies looking at the acceptability of the vaccine 
demonstrated that most parents were in favor of vaccinating their daughters 
after certain criteria were achieved including: whether the parent understood 
its effectiveness, whether the vaccine was recommended by a physician, and 
whether HPY infection was probable. Initial roadblocks cited included cost, 
and concerns that vaccination promoted earlier sexual activity in young girls 
(12). Looking at the last five years, very little has changed in either of these 
obstacles. The price of vaccination has remained high for those with no 
insurance and over 18 years of age, totaling about $360 for the series of three 
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vaccinations, while the cost of other childhood vaccinations that protect 
against multiple diseases are all less than $50. Likewise, parents opposing 
vaccination remain vigilant that early vaccination will both increase their 
child's sexual activity, and condone risky sexual behavior (13). Since CDC 
recommendations for this particular vaccine are for an older age group than 
other childhood vaccinations, parents worry about any possible questions their 
children may have. Accurately and responsibly fielding these questions is 
something parents most likely fear because of ideas it may ignite in young 
impressionable minds (14). 
There were many preconceptions about the HPV vaccine even prior to its 
release in 2006. One study in the late 1990s surveyed adolescents about how 
they believed teenage behavior would change after receipt of the vaccine. 
Surprisingly, 77% believed there would be a substantial increase in risky 
sexual behavior (15). It is easy to ascertain that if adolescents have this 
misconception, that even greater numbers of parents would have similar 
notions about the vaccine. 
Years after landmark trials demonstrated the link between HPV and 
cancer prevention, poor acceptance of the vaccine continued, alerting us to 
problems requiring further attention. One study reported findings from 
telephone surveys of parents of young girls in public schools aged 11-18 years 
in economically disadvantaged areas in Los Angeles, California between 
2007-2008. More than two years after the vaccine release, parents echoed 
earlier sentiments that the vaccine may be harmful, costly, that their daughter 
wasn't old enough to receive protection against an STI, and that the vaccine 
may lead to sexual activity (16). Additionally, 75% of surveyed parents were 
familiar with the HPV vaccine. Of these, 75% were aware that their daughter 
was eligible for the vaccine, and that it would be most beneficial prior to the 
onset of sexual activity ( 16). This study clearly demonstrates that even though 
the public is educated about the ability and benefits of the vaccine, 
misconceptions about its side effects remain and need to be further addressed. 
Future generations would be better served if socio-cultural pressures did not 
affect the prevention of cancer. 
In this chapter, we analyzed clinical data to investigate if the claims of 
change in sexyal behavior following HPV vaccination were true. 
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OUR STUDY 
All patients in our adolescent medicine clinic are screened for all risk 
behaviors, including sexual activity at their initial visit, then the risk behaviors 
are updated on each visit. Adolescent female patients attending our adolescent 
clinic who were also receiving the HPV vaccine were chosen as participants 
for our retrospective study. We analyzed the risk assessment forms for 
qualifying females at various time points including prior to vaccination, upon 
completion of the vaccination series, and one year later. This method provides 
clinical data at different time points with reference to vaccination, allowing us 
to explore changes in sexual behavior. All adolescent girls who have received 
the vaccine were included in the study. Sexual activity data prior to the start of 
the vaccine series and at I year after completion of the series were analyzed. 
However, such a method is not without limitations, assuming that all 
outcomes can be measured through these observed variables even if they are 
partially affected by socio-environmental sources. In other words, it neglects 
the social and environmental influences on the dynamics of teenage behavior. 
Regardless, it is still useful to explore the assertion that vaccination will lead 
to promiscuity since our observations on sexual behavior are in the same 
individuals. A simple comparison of sexual activity at these separate points in 
time can guide future research. We present the results of applying a non-
parametric approach to comparing sexual behavior in the same individuals. 
FINDINGS 
There were 499 female adolescents who received the vaccine. At the time of 
the first vaccination, the average age of the sample was 16.05 (sd=2.9); 51.4% 
of the sample was not sexually active i.e. claiming to have zero partners; the 
average age of the sexually inactive group was 14.89 (sd=2.98); 12% of the 
total were smokers; 8% had abnormal PAP results; 6.8% had prior diagnosis 
of HPV. The variable ' number of partners' was used to investigate change in 
sexual behavior following vaccination. 
Our first and most pressing question was whether there was a significant 
change in the sample's sexual behavior following the vaccination. Since data 
collected is from the same individuals at different points in time, a matched 
(related samples) non-parametric Wilcoxon signed rank test was carried out. 
Merrick, Joav, Tenenbaum, Ariel, and Omar, Hatim A., eds. Adolescence and Sexuality : International Perspectives. Hauppauge, NY, USA: Nova Science Publishers, Inc., 2014. ProQuest ebrary. Web. 12 December 2014.
Copyright © 2014. Nova Science Publishers, Inc.. All rights reserved. 
United States 181 
At time 1, the start of the vaccination series, 51.4% of the sample claimed 
to be sexually inactive by not having a partner. At the end of one year, 51.2% 
of the sample again claimed to be sexually inactive. Obviously, a change of 
0.2% is insignificant and does not warrant statistical analysis. Additionally, 
one year after vaccination, 2.8% of sexually inactive became active by having 
at least one partner. Alternatively, 2.6% of sexually active became inactive 
after one year. Again, these are relatively minor changes and do not warrant 
statistical analysis. 
On the other end of the spectrum is further analysis of the sexually active 
group. In the sample, 22.6% of claimed to have three or more partners at time 
1. After one year, this decreases to 22.4%. Again, a change of 0.2% is very 
minor and does not warrant statistkal analysis. Of those claiming to have more 
than three partners, one year later 4.5% were sexually inactive. Conversely, of 
those who had 3 or more partners after one year, 1.8% had none, 0.9% had 
one, and 0.9% had 2 partners at time 1. Again, these are insignificant changes 
that do not require further analysis. 
DISCUSSION 
The premise of this study is to explore the assertion that preventative health 
care in the form of HPY vaccination in pre-adolescents will lead to 
promiscuity. Two significant issues stem from this assertion. First, we begin to 
question the nature of healthcare programs in the medical context, and also in 
terms of its morality and socio-cultural phenomena. Second, we begin to 
question adolescents ' ability to make decisions. Both of these issues are 
extremely complex, governed by dynamics of human behavior (17,18) It is 
difficult to accurately quantify the effects of continuous exposure to sexual 
material associated with the HPY vaccine in each distinct adolescent who may 
or may not have had any previous exposure from the media, personal 
experiences, parents, or even sexual education courses. How could we assess 
the interaction between this continuous background exposure with health and 
social policies in adolescent care? And would this so called 'negative' 
publicity taint adolescents ' decision making? In other words, an asse1tion that 
obviously associates a healthcare program with sexual activity may in fact be 
counterproductive and detrimental ; by doing so, we increase exposure to 
sexual behavior, ignore the adolescents' process of decision making, and most 
importantly, make unsubstantiated assertions. 
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We quantify sexual activity of adolescents tlu·ough the variable 'number 
of partners,' to explore adolescent sexual behavior. However, this clinical 
dataset is still limiting. The dataset used in this paper only provides number of 
partners as reported by the participants at the time of each visit. There is no 
objective way to verify this information. Nevertheless, analysis of our dataset 
still yields the important conclusion that essentially sexually non-active 
adolescents remain sexually inactive after vaccinations. Furthermore, there is 
also some indications that change in behavior may be in both directions; a 
small proportion of those who had no partners at time one appear to have at 
least one partner one year later which is still less than would be expected by 
age change, and, conversely, a small proportion of those with at least one 
partner at time one appear not to have a partner a year later. If these results 
accurately reflect adolescent behavior in the general population, we presume 
that vaccination and sexual behavior are unrelated. Moreover, we speculate 
that at least in the short tenn, the real issue at hand is the social and cultural 
factors. 
Based on the results of this study, vaccinating young girls with the HPY 
vaccine does not alter their sexual behavior in a significant manner. 
Considering the health benefits of the vaccine, fear of a potential change in 
sexual behavior which does not seem to actually exist, should not get in the 
way of providing the protection against serious illnesses that the vaccine 
provides. 
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